Debrisoquine oxidation polymorphism in a Tasmanian population
- PMID: 1884730
- DOI: 10.1007/BF00315235
Debrisoquine oxidation polymorphism in a Tasmanian population
Abstract
The debrisoquine hydroxylation phenotype was studied in 152 unselected healthy Tasmanian subjects, who were mostly Caucasians of British ancestry. Following a 10 mg oral dose of debrisoquine (D), the ratio of D/4-hydroxydebrisoquine excreted in 8-h urine (metabolic ratio, MR) was determined. MR values were bimodally distributed. Thirteen subjects (8.6%) had MR values from 13.8 to 93.3 and were considered to be poor metabolisers of D, while the others were extensive metabolisers with MR values of 0.04 to 5.4. The D hydroxylation phenotype was not associated with sex. These findings confirm the constancy of D polymorphism in a Caucasian population even after migration to another country.
Similar articles
-
Evidence for the polymorphic oxidation of debrisoquine in the Thai population.Br J Clin Pharmacol. 1990 Feb;29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x. Br J Clin Pharmacol. 1990. PMID: 2306417 Free PMC article.
-
Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.Br J Clin Pharmacol. 1988 Dec;26(6):791-5. doi: 10.1111/j.1365-2125.1988.tb05321.x. Br J Clin Pharmacol. 1988. PMID: 3242585 Free PMC article.
-
Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.Hum Toxicol. 1988 May;7(3):273-6. doi: 10.1177/096032718800700308. Hum Toxicol. 1988. PMID: 3391625
-
Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.Pharmacol Toxicol. 1990 Oct;67(4):273-83. doi: 10.1111/j.1600-0773.1990.tb00830.x. Pharmacol Toxicol. 1990. PMID: 2077517 Review.
-
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001. Clin Pharmacokinet. 1986. PMID: 2868819 Review.
Cited by
-
Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.Eur J Clin Pharmacol. 1991;40(6):547-52. doi: 10.1007/BF00279967. Eur J Clin Pharmacol. 1991. PMID: 1884734
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources